Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A LONG-TERM, OPEN-LABEL EXTENSION STUDY OF TOFACITINIB (CP-690,550) FOR THE TREATMENT OF PSORIATIC ARTHRITIS

Next Previous
Trial Profile

A LONG-TERM, OPEN-LABEL EXTENSION STUDY OF TOFACITINIB (CP-690,550) FOR THE TREATMENT OF PSORIATIC ARTHRITIS

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 02 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tofacitinib (Primary) ; Methotrexate
  • Indications Psoriatic arthritis
  • Focus Adverse reactions; Registrational
  • Acronyms OPAL BALANCE
  • Sponsors Pfizer

    • Most Recent Events

    • 15 Nov 2023 Results of post hoc analysis (n=180) assessing tofacitinib efficacy and safety in pts with PsA presented at the ACR Convergence 2023
    • 03 Jun 2023 Results of pooled data from (NCT01877668/NCT01882439/NCT03486457/NCT01976364) assessing ong-term safety/efficacy of tofacitinib in TNFi-inadequate responder (IR) and biologic disease-modifying antirheumatic drug (bDMARD)-naive PsA pts presented at the 24th Annual Congress of the European League Against Rheumatism
    • 06 Jun 2020 Results (n=180) of sub-study of OPAL-BALANCE assessing tofacitinib 5mg as monotherapy after methotrexate withdrawal with background methotrexate in patients with psoriatic arthritis, presented at the 21st Annual Congress of the European League Against Rheumatism.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top